The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Kipres Generics Earn Bronchial Asthma Indication in Droves
November 10, 2016
- MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
November 10, 2016
- Takeda to Collaborate with 2 Universities on Application of Miniature Liver Technology to Drug Discovery Research
November 10, 2016
- Kipres AG’s Market Penetration Faster than Expected: Kyorin President
November 9, 2016
- Teva Takeda Pharma “Not a Threat” at Present: Nichi-Iko Pres. Tamura
November 9, 2016
- BIKEN, Mitsubishi Tanabe to Form Vaccine JV Next May
November 8, 2016
- Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
November 8, 2016
- Ono's Revenue and Profits Soar as Opdivo Sales Jump 1,714%
November 8, 2016
- MSD’s New Dual Oral Hep C Therapy to Challenge Harvoni; Effective Regardless of Resistance Mutations, Renal Impairment
November 8, 2016
- Japan Diabetes Market Likely to Grow 40% by 2024: Fuji Keizai
November 7, 2016
- Eisai’s Halaven Clinches NICE OK as 3rd-Line Breast Cancer Therapy
November 7, 2016
- Mitsubishi Tanabe to Offer Compound Library to Univ. of Tokyo
November 7, 2016
- Acne Med Epiduo Gel Hits Japan Shelves: Maruho
November 7, 2016
- JCR to Provide Temcell for IIT in Epidermolysis Bullosa
November 4, 2016
- Santen Profits Tumble Over 70% on Strong Yen, Divestment; Ophthalmology Biz Brisk
November 4, 2016
- Pfizer Japan Calls Off Transfer of Innovative Drugs after Global Split Plan Scrapped
November 4, 2016
- Mitsubishi Tanabe Licenses Cell Therapy Agent for Knee Osteoarthritis from S. Korean Firm
November 4, 2016
- Mitsubishi Tanabe Ekes Out Sales Rise on Simponi, Other Major Products
November 2, 2016
- Harvoni Top-Seller Drug in Japan in July-September: QuintilesIMS
November 2, 2016
- Strong Yen Dampens Sales of 4 Japanese Majors, but Global Brands Keep Up Momentum
November 2, 2016
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…